News und Analysen

Generating passive income is great for investors, and holding dividend-paying stocks is an excellent way to do that. However, not all corporations that pay dividends will be attractive to income

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the

ProKidney (NASDAQ: PROK) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.

The chronic kidney disease-focused biotech

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million

Normally, a buy-and-hold strategy pays off, and investors expect to see strong gains from their investments. The S&P 500 (SNPINDEX: ^GSPC) has risen by 200% over the past decade, and mirroring the

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the

Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.

Three Motley Fool contributors think they've found no-brainer stocks to buy

Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the

In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and

For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases

While the market has returned to new highs, not every growth stock has rebounded at the same pace. Five stocks still down 20% or more from all-time highs that look attractive are Advanced Micro

Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy. Regardless of what

Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this

In today's video, I discuss recent updates impacting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the short video, consider

Regardless of the number of tools and resources available to Wall Street or the average investor, there's no way to predict how a stock's price will move with 100% certainty.

However, one thing that

In today's video, I discuss recent updates impacting Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the special offer link below.

Nektar Therapeutics (NASDAQ: NKTR) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling

AstraZeneca (NASDAQ: AZN) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that

One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped

There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics

When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.

Palantir Technologies is on an unstoppable tear. Even after a strong performance in 2024 where it soared 341%, it's up another 78% so far this year. Every time it seems the stock may be running out

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the